Abbott URIprobe becomes first gonorrhea/chlamydia gene amplification test on U.S. market.
This article was originally published in The Gray Sheet
Executive Summary
ABBOTT LCx URIPROBE GONORRHEA/CHLAMYDIA GENE AMPLIFICATION TEST is being priced "just above" the $4-8 charged for the LCx test for chlamydia only, the company says. FDA clearance of Abbott's gene amplification gonorrhea test enables the firm to package the two sexually transmitted disease tests together as the URIprobe.
You may also be interested in...
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.
More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths
Abbott initiated a recall in February of thousands of Heartmate devices due to a system obstruction that can result in serious health outcomes, including death. The FDA has now designated the recall as class I.
‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs
As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.